This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kennedy, B. J. Articles by Sandberg-Wollheim, M. Search for Related Content PubMed PubMed Citation Articles by Kennedy, B. J. Articles by Sandberg-Wollheim, M.

Effect of Mithramycin on a Mouse Glioma¹

Department of Medicine, University of Minnesota Medical Center, Minneapolis, Minnesota 55455

Mithramycin is an effective antitumor agent in the clinical treatment of disseminated embryonal cell carcinoma of the testis, hypernephroma, and glioblastoma multiforme. Despite its marked antibacterial activity and cytotoxic action in tissue culture, mithramycin has not shown significant activity against the experimental animal tumors currently employed in screening studies of anticancer agents.

Mithramycin was administered to C57 black mice with a transplantable glioma tumor. The maximum tumor inhibition was 40% of that of the control tumors. When mithramycin was administered 3 times every week, the duration of inhibition was extended. Prolonged therapy was associated with accumulated drug toxicity. This tumor system has been of value in the study of the mechanisms of mithramycin activity. The drug appears to exert its cytotoxic effect by inhibition of RNA synthesis.

¹ This investigation was supported by Grants CA-3143, CA-05862, T4 CA-5158, CA-08832, and CA-08344 from the National Cancer Institute, USPHS.

Received 5/ 1/67. Accepted 9/ 8/67.